Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17626104 | 0.81 | LMNA (0.34) | METAP2ALDH1A1KMT2ARAB9ANPC1 | |
| SCHEMBL69540 | 0.81 | KDR (0.40) | ALDH1A1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1900288 | 0.79 | BACE1 (0.41) | IDO1RAB9ANPC1TSHRSMN1; SMN2 | |
| SCHEMBL9955273 | 0.79 | HSD17B1 (0.45) | IDO1MEN1KMT2AHSD17B1HSD17B2 | |
| SCHEMBL17028871 | 0.76 | IDO1 (0.46) | IDO1ALDH1A1RAB9AXDHADORA1 | |
| SCHEMBL4757273 | 0.74 | ACHE (0.41) | IDO1METAP2ALDH1A1MEN1KMT2A | |
| SCHEMBL8876829 | 0.72 | KDM4E (0.50) | ALDH1A1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL209262 | 0.71 | MAPT (0.42) | IDO1ALDH1A1HPGDKDR | |
| SCHEMBL1416534 | 0.70 | ACHE (0.41) | IDO1METAP2ALDH1A1MEN1KMT2A | |
| SCHEMBL19741486 | 0.70 | HSD17B1 (0.56) | ALDH1A1MEN1KMT2AHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | claimed |
| US-20100137297-A1 | SPIROINDALONES | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | claimed |
| CN-101678011-A | Spiro-indolinone compounds | MERCK & CO INC | 2010-03-24 | — | — | CN | claimed |
| EP-2160187-A1 | SPIROINDALONES | Merck Sharp & Dohme Corp. (US) | 2010-03-10 | — | — | EP | claimed |
| WO-2008144266-A1 | SPIROINDALONES | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | claimed |
| EP-2160187-B1 | SPIROINDALONES | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8309544-B2 | Spiroindalones | MERCK SHARP & DOHME CORP. (US) | 2012-11-13 | — | — | US | disclosed |
| CN-101678011-B | Spiro-indolinone compounds | MERCK SHARP & DOHME | 2012-07-18 | — | — | CN | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20100137297-A1 | SPIROINDALONES | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| CN-101678011-A | Spiro-indolinone compounds | MERCK & CO INC | 2010-03-24 | — | — | CN | disclosed |
| EP-2160187-A1 | SPIROINDALONES | Merck Sharp & Dohme Corp. (US) | 2010-03-10 | — | — | EP | disclosed |
| WO-2008144266-A1 | SPIROINDALONES | MERCK & CO., INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137297-A1 | SPIROINDALONES | HIF1AN, HIF1A, EGLN2 | IDO1 2073/4885METAP2 3750/4885ALDH1A1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.